Pfizer to Pay Billion for Seagen, Set Post-Covid Course (2)
Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its cours...
Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma. Pfizer will pay $229 a share in cash for Bothell, Washington-based Seagen, according to a statement Monday, about a third more than the drugmaker's closing share price Friday. It expects the deal to close late this year or early 2024. Seagen shares rose 16% as of 1:06 p.m. in New York, bringing its market value to $37.